NCT04874038 2025-11-17
Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN)
University Health Network, Toronto
Phase 3 Recruiting
Clinical Trials
16 trialsNCT05703178 2025-07-25
Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia
Northwestern University
Phase 3 Recruiting
NCT01964378 2021-07-15
CORAL
Tris Pharma, Inc.
Phase 3 Terminated
NCT02031432 2021-07-15
CORAL XT
Tris Pharma, Inc.
Phase 3 Completed
NCT02367820 2021-06-22
SUMMIT-LTS
Nektar Therapeutics
Phase 3 Completed
NCT01789216 2021-02-03
PAIN
Major Extremity Trauma Research Consortium
Phase 3 Completed
NCT01264887 2019-11-04
Tapentadol in Chronic Malignant Tumour Related Pain
Grünenthal GmbH
Phase 3 Terminated
NCT00696137 2019-09-24
Long-term Extension Study of BEMAâ„¢ Fentanyl
BioDelivery Sciences International
Phase 3 Completed
NCT02408393 2019-07-10
MIRs03
Institut Curie
Phase 3 Completed
NCT02603705 2018-03-05
Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain
Egalet Ltd
Phase 3 Completed
NCT02232256 2017-04-26
CALPXT96
9305-9954 Quebec Inc
Phase 3 Withdrawn
NCT02303847 2015-05-27
Ketamine
University of Washington
Phase 3 Unknown
NCT01206907 2012-08-17
Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects
Endo Pharmaceuticals
Phase 3 Withdrawn
NCT00126789 2012-06-05
Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Moderate to Severe Cancer Pain
ZARS Pharma Inc.
Phase 3 Terminated
NCT00410748 2010-04-27
Safety and Tolerability of Long-Term Administration of Hydromorphone HCI CR (Controlled Release)
Alza Corporation, DE, USA
Phase 3 Completed
NCT00911261 2010-02-15
Oxymorphone Extended Release in Patients With Cancer or Neuropathic Pain
Endo Pharmaceuticals
Phase 3 Completed